US Bancorp DE Trims Holdings in BioNTech SE (NASDAQ:BNTX)

US Bancorp DE reduced its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 81.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,678 shares of the company’s stock after selling 21,012 shares during the period. US Bancorp DE’s holdings in BioNTech were worth $556,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of BNTX. Janney Montgomery Scott LLC purchased a new position in shares of BioNTech during the first quarter worth about $314,000. QRG Capital Management Inc. increased its holdings in shares of BioNTech by 32.9% in the first quarter. QRG Capital Management Inc. now owns 16,731 shares of the company’s stock valued at $1,543,000 after purchasing an additional 4,144 shares during the period. ProShare Advisors LLC raised its stake in shares of BioNTech by 10.4% during the first quarter. ProShare Advisors LLC now owns 6,785 shares of the company’s stock worth $626,000 after purchasing an additional 637 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of BioNTech by 2.3% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after purchasing an additional 223 shares during the period. Finally, Midwest Professional Planners LTD. grew its position in BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Trading Up 2.6 %

BioNTech stock opened at $110.64 on Monday. The stock has a 50-day moving average price of $111.85 and a 200 day moving average price of $96.66. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The stock has a market cap of $26.31 billion, a PE ratio of -52.69 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 earnings per share. Equities research analysts predict that BioNTech SE will post -3.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BNTX shares. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the stock from $90.00 to $137.00 in a research note on Friday. Deutsche Bank Aktiengesellschaft raised their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Bank of America lifted their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, HC Wainwright upped their price target on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.54.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.